BioStructures Cleared to Market Collagen Bone Graft

Newport Beach, Calif., devicemaker BioStructures received FDA clearance to market its next-generation Silhouette Mineralized Collagen Scaffold Bone Graft. The graft, comprised of biphasic materials within a woven network of collagen fibers, is designed to boost healing, the firm said Thursday.

The MCS bone graft represents a new class of synthetic biomaterials designed for optimized handling during a procedure and increased responsiveness at the wound site, BioStructures said. The matrix is 90 percent porous, which helps to optimize delivery of bone marrow aspirate and other biologic factors crucial to the healing process.

The company said that together the composition and structure of the MCS graft support bone bonding and sustained remodeling as the healing process progresses. — Kellen Owings